News | December 16, 2010

Customized Solutions Meet the Demands of an Evolving Radiology Market

December 16, 2010 – Bracco Imaging demonstrated how its customized evidence-based diagnostic imaging solutions are meeting the demands of an evolving radiology market at the Radiological Society of North America (RSNA) meeting. The company is also showing regulatory progress related to its contrast media in computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine, cardiac catheterization, interventional/diagnostic radiology and its contrast delivery systems.

“A number of factors are shaping the evolution of radiology today, including rapid innovation, cost control and an acute awareness of product safety,” said Carlo Medici, head of global commercial operations of Bracco Imaging and president and CEO, Bracco Diagnostics.

The company’s Isovue (iopamidol injection) is available in a convenient range of iodine concentrations and packaging options, making it the top osmolar contrast media agent in the United States.

The company also continues to see robust growth stemming from its 2008 acquisition of E-Z-EM, one of the most recognized brands among radiologists and gastrointestinal (GI) physicians. Among these are the company’s injector and data management systems, which enable radiologists, administrators and technologists to gain workflow efficiencies, imaging optimization and patient safety benefits. Also, through this acquisition, Bracco is now the only provider of barium-based oral imaging products.

Safety, Efficacy and Efficiency in MRI

The company’s gadolinium-based contrast agents (GBCAs) - MultiHance (gadobenate dimeglumine) and ProHance (gadoteridol) - are increasingly the MRI agents of choice by radiologists in more than 2,000 healthcare facilities in the United States.

MultiHance was the first and only contrast agent approved for MRI of the central nervous system (CNS) in the United States, with twice the relaxivity compared to other tested extracellular contrast agents. This means greater contrast-to-noise and lesion-to-brain ratio, which may lead to improved visualization. ProHance is the only macrocyclic gadolinium contrast agent available in the United States, with an exceptionally stable Gd chelate.

Nephrogenic systemic fibrosis (NSF), a rare and potentially life threatening syndrome in patients with renal impairment, has been associated with GBCAs. This has fueled significant clinical and scientific activity in attempts to determine the etiology of this disease. In response the U.S. Food and Drug Administration (FDA) recently published new guidelines defining specific classes of GBCAs based on risk of causing NSF. In a briefing document dated December 8, 2009, the FDA wrote: “Of the 5 GBCs considered, the higher risk is associated with Omniscan, Magnevist, and OptiMARK while the lowest risk is associated with ProHance and MultiHance.”

Further, the American College of Radiology that radiologists should administer GBCAs to renally impaired patients only where necessary. The ACR also advised using the lowest possible dose.

Studies demonstrate that MultiHance provides significantly greater diagnostic information and lesion visualization when compared to two other commonly used contrast agents used at an equivalent dose. It is also FDA-approved for intravenous use in MRI of the CNS in children over two years of age.

For more information: usa.braccoimaging.com

Related Content

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
Overlay Init